Highest-materiality recent filing
Protagenic Therapeutics unwinds Phytanix Bio acquisition, pays $310k, settles litigation
Settlement and Unwind Agreement executed Feb 17, 2026; SEA dated May 15, 2025 terminated.
Protagenic Therapeutics receives Nasdaq delisting notice; trading to move to OTC Jan 5, 2026
Nasdaq determined to delist PTIX and PTIXW due to failure to meet minimum stockholders' equity (Rule 5550(b)(1)) and timely filing (Rule 5250(c)(1)).
Protagenic Therapeutics receives Nasdaq delisting notice for equity and filing non-compliance
Stockholders' equity fell below $2.5M minimum per Listing Rule 5550(b)(1) as of June 30, 2025.
Protagenic Therapeutics files suit to rescind Phytanix Bio acquisition or seek damages
Filed Verified Complaint in Delaware Chancery Court on October 28, 2025.
Protagenic restructures after Phytanix acquisition; CEO/COO out, targets $8M savings
Acquired Phytanix Bio on May 15, 2025 via share exchange; gained five preclinical candidates (PHYX-001 to -005).
Protagenic: Nasdaq non-compliance for late 10-Q; auditor changed; PT00114 Phase I dosing complete
Dismissed MaloneBailey as auditor, engaged Green Growth CPAs as new independent auditor effective August 7, 2025.
Protagenic Therapeutics restructures, cuts ~$8M annual costs; CEO and COO terminated
Board approved restructuring to virtual model, focusing on PT00114 Phase 2 trial expected to complete in 9–12 months.
Protagenic Therapeutics receives $3.1M from warrant exchanges and exercises
Warrant exchanges and exercises over the last four trading days generated $3.1M in cash.
Protagenic Therapeutics acquires Phytanix Bio in share exchange, appoints new CEO and directors
Acquired 100% of Phytanix Bio common shares from Alterola Biotech and EMC2 Capital as of May 15, 2025
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
Colin Stott as Chief Operating Officer and as a director of the Company
Colin Stott as Chief Operating Officer and as a director of the Company
Jennifer Chao as a director of the Company
appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company
appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
promoted Andrew Slee from his prior role of Chief Operating Officer to the Company’s Chief Development Officer, effective immediately upon the Closing on May 15, 2025
Max materiality 0.90 · Median 0.60 · Most common event other_material